Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women
NCT ID: NCT04652232
Last Updated: 2020-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2016-12-05
2017-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Premature termination of anagen into catagen and telogen hair follicle is the main mechanism observed in TE. It results in increased, synchronized telogen shedding leading to a decrease in global hair density.
Acute telogen effluvium (ATE) has an abrupt onset and generalized scalp hair loss occurring 2-3 months after a triggering event, which could be unidentifiable in up to 33% cases.
The degree of effluvium depends on the severity, duration of exposure and the type of agent, that can be: emotional stress, hormonal changes in the postpartum period, high fever, surgery, surgical/accidental trauma, severe haemorrhage, chronic systemic illness, or immense psychological stress, changes in medication or crash-diets. A summer effect possibly ultraviolet (UV) light induced, manifesting itself in autumn can cause ATE. The incidence of TE is not known, although it is likely that most women will experience at least 1 episode of TE during a lifetime.
ATE can be diagnosed based on relevant medical and personal history and examination subjective complaints, clinical and physical exams or relevant investigations (hair pull test, phototrichogram, blood test…). ATE generates a lot of anxiety in the patient: significant impact on quality of life, self-esteem impairment, and stress increase. Thus, stress may act as a primary inducer; an aggravating factor or be a response to hair loss.
ATE usually remits within few months (3-4 to 6 months) in 95% of cases if the trigger is removed or treated. Complete recovery may take until 1 year. A resolving TE is characterized by the absence of hair shedding, a negative hair pull test and synchronized hair growth.
In this study, our aim is to assess the effects of the RV3466F lotion on hair growth, compared to a control group, with clinical and biometrological non- invasive methods on an adult female population with telogen effluvium.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Moreover, due to the type of product (lotion) and the area of application ( scalp), the parallel groups design is adapted to the study purpose.
To increase the adherence to the study protocol and to limit the negative psychological impact of hair shedding without treatment, the control group receive a neutral shampoo (extra mild shampoo).
In order to avoid a bias between groups regarding the associated products, the same shampoo is given for the two groups. It should be used at the usual frequency. The allocation of the study product is randomized.
Only women are included in the study as specified in the claim of the study product.
The study area is the whole scalp. For evaluations the scalp is divided into 4 parts: centroparietal, parietal (right/left), frontal, and occipital areas The concerned part of the scalp which is evaluated can change according to the outcome measure.
The Phototrichogram (PTG) is a painless, non-invasive and objective method, used done in 2 steps 48 hours apart to provide an accurate chronological following of hair growth on a specific scalp area . All data and images are computerized, which enables a semi-automatic quantification of hair growth variables (density, growth…). A preliminary dyeing of the hair is performed, in order to enhance the contrast between hair and scalp.
The hair pull test is a semi quantitative method usually used to diagnose ongoing hair shedding and it helps to assess severity and location of hair loss.
Global photographs help to illustrate the scalp hair coverage and the overall course of hair volume. For a better standardization of the shooting conditions, a stereotactic device is used, allowing their comparison from time to time, which is done ideally by trained people, the photographs being subsequently time blinded.
The 60 seconds hair count test is a non-invasive and painless test performed by the subject itself, on the whole scalp in order to count the total number of hairs shed during a 60 seconds combing.
The clinical study includes 9 visits:
* Visit 1 - Selection (D1)
* Visit 2 - Inclusion - 48 hours (±2h) after V1
* Visit 3 - Intermediate - 4 weeks (D29 ± 4 days)
* Visit 4 -Intermediate - 48 hours (±2h) after V3
* Visit 5 - Intermediate - 8 weeks (D57 ± 4 days)
* Visit 6 - Intermediate - 48 hours (±2h) after V5
* Visit 7- Intermediate - 12 weeks (D85 ± 4 days)
* Visit 8 - Intermediate - 16 weeks (D113± 4 days)
* Visit 9 - Study end: 48 hours (±2h) after V8
The maximal duration of participation for a subject is 119 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
The investigator will only dispense the study product to the subjects included and randomized.
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treated group
This group will receive the RV3466F lotion and a neutral shampoo
RV3466F lotion
Code: RV3466F Formula: MF5354
Application modalities:
3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.
Shampoo should be avoided within the 2 hours after application
Shampoo
Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031
Application modalities:
as often as usual
For the treated group only : no shampoo within the 2 hours after lotion application
Control group
This group will receive a neutral shampoo
Shampoo
Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031
Application modalities:
as often as usual
For the treated group only : no shampoo within the 2 hours after lotion application
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RV3466F lotion
Code: RV3466F Formula: MF5354
Application modalities:
3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.
Shampoo should be avoided within the 2 hours after application
Shampoo
Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031
Application modalities:
as often as usual
For the treated group only : no shampoo within the 2 hours after lotion application
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject having a proportion of hair in telogen phase superior to 15% (determined by phototrichogram at inclusion) on the centroparietal area of the scalp
* Subject having a total hair density superior or equal to ≥ 220 hairs/ cm2 (determined by phototrichogram at inclusion) on the centroparietal area of the scalp
* Criteria related to treatments and products:
* Any hair care product applied on the scalp between the selection visit and the inclusion visit (e.g. gel, hairspray, wax, foam, …) or water or brushing.
* Reaction to the used hair dye during the inclusion visit
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yorik Dr DROUAULT
Role: PRINCIPAL_INVESTIGATOR
INTERTEK FRANCE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de santé SABOURAUD C.E.P.C
Paris, , France
INTERTEK
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RV3466F2016362
Identifier Type: -
Identifier Source: org_study_id